HMGN2P30: A Drug Target / Disease Biomarker (G100131183)

Target Name: HMGN2P30

NCBI ID: G100131183

HMGN2P30

Other Name(s): high mobility group nucleosomal binding domain 2 pseudogene 30 | High mobility group nucleosomal binding domain 2 pseudogene 30

HMGN2P30: A Drug Target / Disease Biomarker

HMGN2P30, also known as human menin-M2, is a protein that is expressed in various tissues throughout the body. It is a key player in the meningioma, a type of brain cancer that is characterized by the buildup of glial cells, which support and protect nerve cells.

Recent studies have identified HMGN2P30 as a potential drug target and biomarker for the treatment of meningioma. By targeting this protein, researchers hope to reduce the growth of glial cells and inhibit the formation of new neurons in the meningioma.

One of the main reasons for the potential of HMGN2P30 as a drug target is its role in the development and progression of meningioma. Meningioma is a type of brain cancer that is characterized by the buildup of glial cells, which support and protect nerve cells. The buildup of these cells is what allows meningioma to grow and progress over time. By targeting HMGN2P30, researchers hope to reduce the number of glial cells and inhibit the formation of new neurons in the meningioma, leading to a reduction in the size and severity of the tumor.

Another potential mechanism by which HMGN2P30 may be used to treat meningioma is its role in the regulation of cell growth and differentiation. Meningioma tumors are characterized by the overproduction of glial cells, which can lead to the formation of new neurons in the meningioma. By targeting HMGN2P30, researchers hope to reduce the production of glial cells and inhibit the formation of new neurons in the meningioma, leading to a reduction in the size and severity of the tumor.

In addition to its potential as a drug target, HMGN2P30 has also been identified as a potential biomarker for the diagnosis and prognosis of meningioma. The buildup of glial cells in the meningioma is a well-established indicator of the severity and stage of the tumor. By targeting HMGN2P30, researchers hope to reduce the number of glial cells and improve the sensitivity of the tumor to chemotherapy, leading to improved outcomes for patients.

Targeting HMGN2P30 also has the potential to be a valuable research tool for the study of neurodegenerative diseases. The buildup of glial cells in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, is a well-established indicator of the severity and progression of the disease. By targeting HMGN2P30, researchers hope to reduce the number of glial cells and improve the sensitivity of the disease to therapeutic interventions, leading to improved outcomes for patients.

Overall, HMGN2P30 is a protein that has the potential to be a drug target and biomarker for the treatment of meningioma. By targeting this protein, researchers hope to reduce the growth of glial cells and inhibit the formation of new neurons in the meningioma, leading to a reduction in the size and severity of the tumor. Additionally, HMGN2P30 has the potential to be a valuable research tool for the study of neurodegenerative diseases and may be used to develop new treatments for these debilitating conditions.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 30

The "HMGN2P30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets